Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19
| |

Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19

On Jul. 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial…

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers formed collaboration to develop Emergent’s COVID-19 hyperimmune globulin product
| | |

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers formed collaboration to develop Emergent’s COVID-19 hyperimmune globulin product

On Jul. 8, 2020, the Mount Sinai Health System, Emergent BioSolutions and ImmunoTek Bio Centers announced a collaboration…

Regeneron announced start of REGN-COV2 phase 3 COVID-19 prevention trial in collaboration with National Institute of Allergy and Infectious Diseases
|

Regeneron announced start of REGN-COV2 phase 3 COVID-19 prevention trial in collaboration with National Institute of Allergy and Infectious Diseases

On Jul. 6, 2020, Regeneron announced initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody cocktail…